Accent Therapeutics, Inc.
@accent_tx
Followers
680
Following
124
Media
108
Statuses
168
Accent is developing oncology-focused, small molecule therapies in the emerging field of RNA modification.
Joined January 2018
Happening now: our #AACR23 presentation on the compelling evidence supporting targeted inhibition of DHX9 as a novel therapeutic modality in MSI-H colorectal cancer. Click here to learn more: https://t.co/ahXTcQRMuA
0
2
5
If you're at the 2023 @GordonConf on RNA Editing this week, you won't want to miss our poster "Discovery of Small Molecule Inhibitors of #ADAR1"!
0
0
5
Thoughtfully building and scaling compound management is essential to efficient, highly-integrated small molecule #drugdiscovery and development - learn more about our approach as shared at #SLAS2023
0
2
6
If you'll be at #SLAS2023, don't miss the chance to see two exciting posters from #TeamAccent!
0
1
3
Congratulations to our founder, Chuan He, on being named a #WolfPrize2023 Laureate in Chemistry for "discovering reversible RNA methylation and its role in the regulation of gene expression"!
0
1
4
We are delighted to welcome Serena Silver to #TeamAccent as our Vice President of Biology! https://t.co/SFULDUQ9OG
#lifesciences #Leaders
0
0
0
Congratulations to our scientific advisor and thought partner, Professor Karen Allen!
The DBC is pleased to announce that Prof. Karen Allen of Boston University is the winner of the inaugural Abeles and Jencks Award for the Chemistry of Biological Processes for 2022! https://t.co/1pGK6AYCYv
@BUChemistry @allenlab @AmerChemSociety
0
0
0
DYK that #TeamAccent is proudly 50% female? Today our hardworking team celebrates #WomenInScience Day and all of the amazing, difference-making #WomenInSTEM!
0
4
3
Today, #WorldCancerDay, and every day, we join the @uicc in promoting greater understanding and recognition of the inequities in cancer care around the globe. Together, we must #CloseTheCareGap.
0
0
1
We are thrilled to welcome Stephen Blakemore to #TeamAccent as our Vice President of Translational Medicine! https://t.co/SFULDUyyq6
#lifesciences #leaders
0
0
2
Congratulations to our co-founder and thought partner, Chuan He!
Introducing Chuan He, the new Editor-In-Chief of ACS Chemical Biology! Read about his vision for the journal, his current research interests, and his advice for young scientists here- https://t.co/6PsSKUjgcG
0
0
0
Coming up! Our Vice President of Molecular Discovery, Ann Boriack-Sjodin, presents at the 4th Annual @RNA_TDD Summit on December 9th! https://t.co/bYwCYRy40x
0
0
0
We are pleased to entrust our #METTL3 program to the innovative team at @IpsenGroup and delighted to share the news of this partnership! #RMPs #RNAModification
https://t.co/4AlKdSYtZr
0
1
10
Our issue this week includes work by Robert A. Copeland, Steve Bourgault, Junichi Taira, Shogo Nakano, Sohei Ito, @clvizcarra and more. Check out issue 29 now at https://t.co/RgRrXWnt4n
@accent_tx @ChimieUqam @kyutech @Barnard_Chem
0
3
9
If you're looking for inspiration on this #InnovationWednesday - you won't want to miss "Chance Favors the Perplexed Mind" out today in @BiochemistryACS from our own Bob Copeland!
pubs.acs.org
Scientific discoveries often start with an observation that does not quite make sense, within the framework of a well-established hypothesis. It is when researchers delve deeply to understand such...
0
1
3
A "must add" for your holiday weekend reading list - our own Bob Copeland's Expert Opinion on the importance and evolution of the drug-target residence time model! Happy #PublicationFriday! https://t.co/ol4451nF6e
tandfonline.com
IntroductionThe pharmacological action of a drug is linked to its affinity for a specific molecular target as quantified by in vitro equilibrium measurements. However, it is clear that for many hig...
0
0
0
A true visionary, oncology thought leader and dedicated patient advocate - José Baselga leaves a powerful and enduring legacy. We are deeply saddened by the news of his passing. Our heartfelt condolences to his family, friends and colleagues.
We are deeply saddened by the news that José Baselga, EVP Oncology R&D, has passed away. An outstanding scientific leader, José leaves a lasting legacy in the scientific community and here at AstraZeneca. We send our condolences to his family. https://t.co/hiVTYIkdKm
0
1
2
On #EmployeeAppreciation Day, and every day, we say THANK YOU to each and every member of #TeamAccent! Your creativity, compassion, teamwork and drive are an inspiration!
0
2
1
Coming up! On March 11th, our President & CSO, Bob Copeland, joins in a discussion on the progress, #therapeutic potential and challenges of targeting #mRNA biology, part of the @demycolton Virtual Salon Series https://t.co/xhbxP7Lx8S
0
0
5
‘We only have three problems and they’re delivery, delivery, delivery’ – Rachel Brazil explores a new route to treating disease https://t.co/Et2yuKiyQK
chemistryworld.com
Some medicinal chemists have changed their focus from proteins to target RNA, finds Rachel Brazil
0
4
3